Anti-Human CD25 Recombinant Antibody (Daclizumab) (CAT#: TAB-023)

Recombinant monoclonal antibody to Human CD25. Daclizumab (trade name daclizumab) is a therapeutic humanized monoclonal antibody. It is used to prevent rejection in organ transplantation, especially in kidney transplants. The drug is also under investigation for the treatment of multiple sclerosis. Daclizumab works by binding to CD25, the alpha subunit of the IL-2 receptor of T cells.

Specific Inquiry Online Inquiry
  • Size:
  • Conjugation:
  • Endotoxin:
  • Purity:
  • Fc Engineering:
  • Published Data
  • Tested Data
  • Gene Expression
  • Datasheet
  • MSDS
  • COA
FC

Figure 1 Flow cytometric analysis of peripheral blood lymphocytes of a patient treated with daclizumab.

Figure 1 Flow cytometric analysis of peripheral blood lymphocytes of a patient treated with daclizumab.

The dot plots in the first two columns are gated on lymphocytes, and those in the third and fourth columns are gated on CD3+cells. Following treatment, p55 is not detected by anti-CD25 nor by anti-humanized Tac (daclizumab) on CD3+ cells (first and second columns), but the CD3+ cells remain positive for HLA-DR (third column) and faintly positive for p55 using 7G7 (fourth column).

Przepiorka, D., Kernan, N. A., Ippoliti, C., Papadopoulos, E. B., Giralt, S., Khouri, I.,... & Champlin, R. (2000). Daclizumab, a humanized anti-interleukin-2 receptor alpha chain antibody, for treatment of acute graft-versus-host disease. Blood, 95(1), 83-89.

ELISA

Figure 2 Absolute numbers of cells after treatment with daclizumab.

Figure 2 Absolute numbers of cells after treatment with daclizumab.

Note the difference in scale of the y-axis between graphs. (A) Absolute number of lymphocytes (ALC) (solid line), CD3 + 56− (dashed line) and CD3 − 56+(dotted line) cells after treatment with daclizumab. (B) Absolute number of CD3 + 56− cells (solid line), CD3+DR+ cells (dashed line), CD3 + 7G7+ cells (dotted line), and CD3 + 25+ cells (thin line) after treatment with daclizumab.

Przepiorka, D., Kernan, N. A., Ippoliti, C., Papadopoulos, E. B., Giralt, S., Khouri, I.,... & Champlin, R. (2000). Daclizumab, a humanized anti-interleukin-2 receptor alpha chain antibody, for treatment of acute graft-versus-host disease. Blood, 95(1), 83-89.

MRI

Figure 3 Change in CEL on brain MRI during daclizumab trial: individual patients (A) and cumulative lesion analysis (B).

Figure 3 Change in CEL on brain MRI during daclizumab trial: individual patients (A) and cumulative lesion analysis (B).

(A) Evolution of new CEL on brain MRI during daclizumab trial. All 11 patients are presented. Group average for each time point is calculated from data on 10 MS patients who received 1 mg/kg daclizumab dosing. (B) Cumulative lesion analysis of new and total CEL during daclizumab trial. Number of new (and total) CEL per each month were added together for 10 MS patients and plotted as a cumulative lesion analysis. There is proportional monthly accumulation of CEL in the whole cohort (as evident from the linear relationship), and daclizumab add-on leads to gradual decrease in cumulative CEL (change in slope) that becomes evident after 1.5–2 months of therapy.

Bielekova, B., Richert, N., Howard, T., Blevins, G., Markovic-Plese, S., McCartin, J.,... & Martin, R. (2004). Humanized anti-CD25 (daclizumab) inhibits disease activity in multiple sclerosis patients failing to respond to interferon β. Proceedings of the National Academy of Sciences, 101(23), 8705-8708.

ELISA

Figure 4 Daclizumab treatment decreases CSF levels of CXCL13 and intrathecal production of IgG.

Figure 4 Daclizumab treatment decreases CSF levels of CXCL13 and intrathecal production of IgG.

(A) CSF CXCL13 concentration was measured by ELISA. (B) IgG index as measured by NIH clinical laboratory. Raw data for individual patients measured before (Baseline) and 6.5 months after initiation of daclizumab therapy (Dac Th) are depicted as gray dot and line blots and group data are depicted as box plots with mean highlighted as red and median as black horizontal line.

Perry, J. S., Han, S., Xu, Q., Herman, M. L., Kennedy, L. B., Csako, G., & Bielekova, B. (2012). Inhibition of LTi cell development by CD25 blockade is associated with decreased intrathecal inflammation in multiple sclerosis. Science translational medicine, 4(145), 145ra106-145ra106.

FuncS

Figure 5 Enhanced intermediate IL-2/IL-15 signaling in daclizumab-treated patients promotes differentiation of ILCs toward functional NK cells (A) Representative pSTAT5 levels of untreated or daclizumab (Dac Th) treated MS patients.

Figure 5 Enhanced intermediate IL-2/IL-15 signaling in daclizumab-treated patients promotes differentiation of ILCs toward functional NK cells (A) Representative pSTAT5 levels of untreated or daclizumab (Dac Th) treated MS patients.

Purified ILCs were stimulated with IL-2 (100IU/ml), IL-7 (10ng/ml), IL-15 (10ng/ml) or no cytokine for 10 minutes (optimal concentrations determined in pilot experiments). ILCs were then immediately fixed and stained for phosphorylated Stat5 production. (B) Group signaling data analogous to (A). (C) Purified c-kit + ILCs cells were cultured for 7 days in media supplemented with SCF and Flt3L (both 10ng/ml) and in the presence of IL-2 (100IU/ml), IL-7 (10ng/ml), IL-15 (10ng/ ml) or no cytokine control. At day 7, cultured cells were stained and analyzed by FACS for the presence of CD56 + NK cells (compared to ex vivo PBMCs of daclizumab-treated MS patients with significant expansion of CD56 bright NK cells). (C) Raw data from a representative experiment and (D) represents group data of the number of CD56 dim NK and CD56 bright NK cells per 1,000 beads. (E) Purified c-kit + ILCs were cultured as in panel C. At day 7, cultured cells were FACS stained for functional NK markers (Perforin, Granzyme A and B; compared to ex vivo PBMC of daclizumab-treated MS patients with significant expansion of CD56 bright NK cells). FACS plots are representative of 4 replications. (F) Also on day 7, cultured cells were incubated for ~16hr with target GFP-tagged K562 cells at a 1:1 effector to target ratio (or K562 cell only control wells). K562 killing was then.

Perry, J. S., Han, S., Xu, Q., Herman, M. L., Kennedy, L. B., Csako, G., & Bielekova, B. (2012). Inhibition of LTi cell development by CD25 blockade is associated with decreased intrathecal inflammation in multiple sclerosis. Science translational medicine, 4(145), 145ra106-145ra106.


Specifications

  • Immunogen
  • The details of the immunogen for this antibody are not available.
  • Host Species
  • Mouse
  • Derivation
  • Humanized (from mouse)
  • Type
  • IgG1 - kappa
  • Specificity
  • Tested positive against native human antigen
  • Species Reactivity
  • Human
  • Applications
  • ELISA, Neut, IF, IP, FC, FuncS, MRI
  • Trade name
  • daclizumab
  • CAS
  • 152923-56-3
  • Generic Name
  • Daclizumab
  • Biological Half-Life
  • 20 days (11–38 days)
  • ATC Code
  • L04AC01
  • DrugBank
  • DB00111
  • UNII
  • CUJ2MVI71Y
  • ChEMBL
  • CHEMBL1201605
  • MW
  • 142,612.1 g/mol
  • Related Disease
  • Multiple sclerosis (MS)

Product Property

  • Purity
  • >97%, by SDS-PAGE under reducing conditions and visualized by silver stain.
  • Storage
  • Store at -20°C for long-term storage. Store at 2-8°C for up to one month. Avoid freeze/thaw cycles.

Applications

  • Application Notes
  • The IL2RA antibody has been reported in applications of ELISA, Neut, IF, IP, FC, FuncS, MRI.

Target

  • Alternative Names
  • Daclizumab;daclizumab;152923-56-3;dacliximab;Ro 24-7375;anti-TAC;DB00111IL2RA;interleukin 2 receptor, alpha;IL2R;interleukin-2 receptor subunit alpha;CD25;p55;IL2-RA;IL-2-RA;TAC antigen;IL-2R subunit alpha;IL-2 receptor subunit alpha;TCGFR;IDDM10;

Product Notes

This is a product of Creative Biolabs' Hi-Affi™ recombinant antibody portfolio, which has several benefits including:

• Increased sensitivity
• Confirmed specificity
• High repeatability
• Excellent batch-to-batch consistency
• Sustainable supply
• Animal-free production

See more details about Hi-Affi™ recombinant antibody benefits.

Downloads

Download resources about recombinant antibody development and antibody engineering to boost your research.

See other products for "Daclizumab"

Afuco™ Anti-IL2RA ADCC Recombinant Antibody (Daclizumab), ADCC Enhanced
This product is an ADCC enhanced antibody produced by our Afuco™ platform. Recombinant monoclonal antibody to Human CD25. Daclizumab (trade name daclizumab) is a therapeutic humanized monoclonal antibody. It is used to prevent rejection in organ transplantation, especially in kidney transplants. The drug is also under investigation for the treatment of multiple sclerosis. Daclizumab works by binding to CD25, the alpha subunit of the IL-2 receptor of T cells.

See other products for "IL2RA"

Intrabody

CAT Product Name Application Type
IAB-B073(A) Recombinant Anti-human IL2RA Intrabody [(D-Arg)9] IF, ELISA, FuncS scFv-(D-Arg)9
IAB-B073(G) Recombinant Anti-human IL2RA Intrabody [+36 GFP] IF, FC, WB, FuncS scFv-(+36GFP)
IAB-B073(T) Recombinant Anti-human IL2RA Intrabody [Tat] WB, CO-IP, FuncS scFv-Tat

Chimeric Antibody

Immunotoxin

CAT Product Name Application Type
AGTO-L027D anti-IL2RA immunotoxin RFT5 (scFv)-DT Cytotoxicity assay, Functional assay
AGTO-L027R anti-IL2RA immunotoxin RFT5 (scFv)-RTA Cytotoxicity assay, Functional assay
AGTO-L028E anti-IL2RA immunotoxin RFT5 (IgG)-PE Cytotoxicity assay, Functional assay
AGTO-L028D anti-IL2RA immunotoxin RFT5 (IgG)-DT Cytotoxicity assay, Functional assay
AGTO-L028R anti-IL2RA immunotoxin RFT5 (IgG)-RTA Cytotoxicity assay, Functional assay

Blocking Antibody

CAT Product Name Application Type
NEUT-1350CQ Mouse Anti-IL2RA Recombinant Antibody (clone 2R12) Block, FC, ICC, IF, IHC, IP, WB Mouse IgG1
NEUT-1356CQ Rat Anti-Il2ra Recombinant Antibody (VMC199) FC, IP, IHC, Block, Depletion Rat IgG1, λ
NEUT-1357CQ Rat Anti-Il2ra Recombinant Antibody (clone 3C7) FC, IP, Inhib Rat IgG2b, κ
NEUT-1358CQ Rat Anti-Il2ra Recombinant Antibody (clone mAb0817) Block, Depletion Rat IgG1
NEUT-1359CQ Rat Anti-Il2ra Recombinant Antibody (clone mAb0845) Block, FC, IHC-Fr, IP Rat IgG1

Neutralizing Antibody

Rabbit Monoclonal Antibody

CAT Product Name Application Type
MOR-1808 Rabbit Anti-IL2RA Recombinant Antibody (clone DS1808AB) IHC, ICC, IP Rabbit IgG

Recombinant Antibody

CAT Product Name Application Type
FAMAB-0197CQ Mouse Anti-IL2RA Recombinant Antibody (clone 2C8) ELISA, WB, FC Mouse IgG1, κ
FAMAB-0198CQ Human Anti-IL2RA Recombinant Antibody (clone 4C1) ELISA, WB, FC Chimeric (mouse/human) IgG1, κ
FAMAB-0199CQ Mouse Anti-IL2RA Recombinant Antibody (clone 4F8) ELISA, WB, FC Mouse IgG2a, κ
FAMAB-0200CQ Human Anti-IL2RA Recombinant Antibody (clone huD1) ELISA, FC, Block Humanized IgG1, κ
FAMAB-0201CQ Mouse Anti-IL2RA Recombinant Antibody (clone D1) ELISA, FC, Block Mouse IgG2a, κ

ADCC Enhanced Antibody

CAT Product Name Application Type
AFC-TAB-004 Afuco™ Anti-IL2RA ADCC Recombinant Antibody (Basiliximab), ADCC Enhanced IF, IP, Neut, FuncS, ELISA, FC ADCC enhanced antibody
AFC-TAB-023 Afuco™ Anti-IL2RA ADCC Recombinant Antibody (Daclizumab), ADCC Enhanced ELISA, Neut, IF, IP, FC, FuncS ADCC enhanced antibody
AFC-TAB-155 Afuco™ Anti-IL2RA ADCC Recombinant Antibody (Inolimomab), ADCC Enhanced IP, IF, FuncS, FC, Neut, ELISA ADCC enhanced antibody

Submit a review or a question
There are currently no Customer reviews or questions for TAB-023. Click the button above to contact us or submit your feedback about this product.
View the frequently asked questions answered by Creative Biolabs Support.

For Research Use Only. Not For Clinical Use.

For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.

Send Inquiry

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

  • 0
  • 0
Cart
    Go to compare

    Go to compare